Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, June 12, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Raghuram Selvaraju Reiterated (ANVS) at Strong Buy and Held Target at $23 on, Jun 12th, 2024
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "Annovis Bio, Inc." (ANVS) at Strong Buy and Held Target at $23 on, Jun 12th, 2024.
Raghuram has made no other calls on ANVS in the last 4 months.
There are 2 other peers that have a rating on ANVS. Out of the 2 peers that are also analyzing ANVS, 1 agrees with Raghuram's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Tyler Bussian of "Brookline Capital" Downgraded from Strong Buy to Hold and Held Target at $9 on, Wednesday, February 28th, 2024
This is the rating of the analyst that currently disagrees with Raghuram
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $26 on, Tuesday, April 30th, 2024
